FHI Clinical Inc. has announced it has partnered with Infectious Disease Research Institute (IDRI) to provide full-service contract research organization capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19. IDRI recently received funding from Celularity launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment as a potential treatment option against the novel coronavirus.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.